Amgen Inc. stock underperforms Tuesday when compared to competitors
Shares of Amgen Inc. AMGN shed 2.39% to $306.86 Tuesday, on what proved to be an all-around favorable trading session for the ...
OpenAI just unveiled enhanced image generator within ChatGPT-4o — here's what you can do now
OpenAI today announced the GPT-4o image generator, introducing advanced image generation capabilities integrated within the ChatGPT-4o language model. The company says that GPT-4o represents a ...
Amgen (AMGN) Receives a Buy from Piper Sandler
Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...
MSNBC15d
Crews begin dismantling Black Lives Matter Plaza in DC
Local government crews in Washington began on Monday morning to remove the Black Lives Matter mural that was painted near the White House nearly five years ago. Errin Haines discusses.March 11, 2025 ...
FXStreet15d
Stocks spiral after Trump admits to 'period of transition' in US economy, but Amgen, Verizon outperform
Dow Jones member Verizon is climbing despite the overall market correction. Amgen's weight loss drug is helping it to outperform the broad market. The NASDAQ opened more than 2% lower on Monday ...
Law15d
Struggles Getting Stakeholder Buy-In Slowing Gen AI Adoption
Generative AI is giving in-house legal teams powerful new tools to speed up document review, surface key evidence and refine case strategies, but getting leadership, IT and external partners on ...
Business Insider16d
Amgen (AMGN) Gets a Buy from Piper Sandler
Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The company’s shares closed last Friday at $324.86.
Forbes16d
Tether And Bitcoin Have A Loud, Routinely Ignored Dollar Problem
SYMBOL - 23 April 2024, Baden-Württemberg, Rottweil: The logos of the cryptocurrencies Bitcoin ... More (BTC), Ethereum (ETH), the stablecoin Tether (USDT) and Binance Coin (BNB) can be seen on ...
Nasdaq18d
Amgen Announces Positive Results From Phase 3 Study Of Rocatinlimab In Atopic Dermatitis
(RTTNews) - Amgen (AMGN) and Kyowa Kirin Co., Ltd. announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell rebalancing ...
Mena FN18d
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 ...
Today18d
Joy Bauer shares her most nourishing breakfast recipes
When it comes to recipes, I have a few nonnegotiables: simple, healthy and delicious! These creations are terrific for when you’re craving a quick breakfast or scrumptious afternoon snack: my ...